{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-007259","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.883624+00:00","generated_at":"2026-06-06T03:26:49.154184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Roivant posts $5.1B net income on $7.1B Telavant sale to Roche; cash at $6.7B","bullets":["Net income $5.1B ($6.37 basic EPS) vs loss of $384.9M a year ago, driven by $5.3B gain on Telavant sale.","Net cash proceeds from Telavant sale ~$5.2B; consolidated cash, cash equivalents and restricted cash $6.7B at Dec 31, 2023.","VTAMA net product revenue $20.7M for Q3; over 300k prescriptions written by ~14k prescribers since launch.","Batoclimab Phase 2 Graves' disease trial shows >50% response rate in initial cohort; additional data ongoing.","Non-GAAP net loss $174.9M; R&D expenses $123.7M; SG&A $197.3M; RVT-2001 development discontinued."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-007259","json":"https://secwatch.observer/filing/0001140361-24-007259.json","markdown":"https://secwatch.observer/filing/0001140361-24-007259.md","text":"https://secwatch.observer/filing/0001140361-24-007259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/0001140361-24-007259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/ef20021494_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:26:49.154184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c6fd4a726f6f21c491f1355bd5c777dd4583b80","claim":"Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2023.","evidence_excerpt":"Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/0001140361-24-007259-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}